



# Corrigendum: Commentary: Probiotic and technological properties of *Lactobacillus* spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis

## OPEN ACCESS

### Edited and reviewed by:

Fabio Minervini,  
University of Bari Aldo Moro, Italy

### \*Correspondence:

Amit K. Tyagi  
akumar6@mdanderson.org;  
amittyagiitd@gmail.com

### Specialty section:

This article was submitted to  
Food Microbiology,  
a section of the journal  
Frontiers in Microbiology

**Received:** 02 April 2019

**Accepted:** 02 July 2019

**Published:** 18 July 2019

### Citation:

Tyagi AK and Prasad S (2019)  
Corrigendum: Commentary: Probiotic  
and technological properties of  
*Lactobacillus* spp. strains from the  
human stomach in the search for  
potential candidates against gastric  
microbial dysbiosis.  
*Front. Microbiol.* 10:1628.  
doi: 10.3389/fmicb.2019.01628

Amit K. Tyagi\* and Sahdeo Prasad

Cytokine Research Laboratory, Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States

**Keywords:** *Lactobacillus reuteri*, *Helicobacter pylori*, probiotics, inflammation, triple therapy

## A Corrigendum on

**Commentary: Probiotic and technological properties of *Lactobacillus* spp. strains from the human stomach in the search for potential candidates against gastric microbial dysbiosis by Tyagi, A. K., and Prasad, S. (2015). *Front. Microbiol.* 6:433. doi: 10.3389/fmicb.2015.00433**

In the original article, there was error in **Table 1** as published. The probiotic efficacy for Emara 2014 and Francavilla 2014 reported a significant increase instead of a non-significant increase.

Additionally, the reference for “Francavilla et al., 2008” in **Table 1** was incorrectly written as “Francavilla, R., Lionetti, E., and Cavallo, L. (2008). Sequential treatment for *Helicobacter pylori* eradication in children. *Gut* 57:1178.” It should be “Francavilla, R., Lionetti, E., Castellaneta, S. P., Magistà, A. M., Maurogiovanni, G., Bucci, N., et al. (2008). Inhibition of *Helicobacter pylori* infection in humans by *Lactobacillus reuteri* ATCC 55730 and effect on eradication therapy: a pilot study. *Helicobacter* 13, 127–134. doi: 10.1111/j.1523-5378.2008.00593.x”.

The corrected **Table 1** and Reference appear below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

**TABLE 1** | Selected clinical trials using *Lactobacillus reuteri* for *H. pylori* eradication treatment.

Treatment	Probiotic(s)	Eradication rate	Probiotic efficacy	References
Triple therapy, Omeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, 14 d	<i>L. reuteri</i> ATCC PTA 6475, <i>L. reuteri</i> DSM 17938, 14 d during therapy + further 14 d, <u>Control</u>	74.3% (26/35) 65.7% (23/35)	Non-significant increase of eradication rate with improved GSRS score and reduction of side effects (taste disorder, diarrhea)	Emara et al., 2014
Three-phase study; pre-eradication (1–28 d), eradication (29–35 d), follow-up (36–96 d), Triple therapy	<i>L. reuteri</i> ATCC PTA 6475, <i>L. reuteri</i> DSM 17938, <u>Control</u>	75% (37/50) 65.9% (33/50)	Non-significant increase of eradication rate but no difference in GSRS score	Francavilla et al., 2014
Pantoprazole 20 mg, 8 weeks	<i>L. reuteri</i> , 8 weeks	14.2% (3/21)	Good tolerability with no side effects	Dore et al., 2014
Levofloxacin 500 mg, esomeprazole 20 mg, amoxicillin 1 g, 7 d	<i>L. reuteri</i> , during therapy + further 7 d <u>Control</u>	80% (36/45) 62.2% (28/45)	Significantly increase of eradication rates and reduction of side effects (Nausea, diarrhea)	Ojetti et al., 2012
Omeprazole 1 mg/kg, amoxicillin 50 mg/kg, clarithromycin 15 mg/kg, 7 d	<i>L. plantarum</i> , <i>L. reuteri</i> , <i>L. casei</i> subsp. <i>rhamnosus</i> , <i>B. infantis</i> , and <i>B. longum</i> , <i>L. acidophilus</i> , <i>L. salivarius</i> , <i>S. thermophilus</i> , <i>L. sporogenes</i> , during therapy <u>Control</u>	82.2% (30/34) 76.4% (26/34)	Non-significant increase of eradication rates; significant reduction of side effects (epigastric pain, nausea, vomiting, diarrhea)	Tolone et al., 2012
Pantoprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg, Triple therapy, 7 d <u>Sequential regimen, 10 d</u>	<i>L. reuteri</i> ATCC55730, during therapy + further 7 or 10 d	63% (52/83) 88% (73/83)	Significantly higher eradication rate and reduction of side effects in sequential regimen	Efrati et al., 2012
Sequential therapy (Details not describe)	<i>L. reuteri</i> ATCC55730, 8 weeks <u>Control</u>	33.8 ± 15% (33) 35.8 ± 15.5% (33)	Significant decrease in Gastrointestinal Symptom	Francavilla et al., 2008
Triple therapy (Details not describe)	<i>L. reuteri</i> , 7 d <u>Control</u>	63% 53%	Lowest incidence of side-effects	Scaccianoce et al., 2008
No drug	<i>L. reuteri</i> SD2112, 8 weeks	69.7 ± 4% (33)	Significant reduction of <sup>13</sup> C-UBT	Imase et al., 2007
Omeprazole 1 mg/kg, amoxicillin 50 mg/kg, clarithromycin 15 mg/kg, sequential therapy, 10 d	<i>L. reuteri</i> ATCC55730 (SD2112) <u>Control</u>	85% (17/20) 80% (16/20)	Significant reduction of GSRS score	Lionetti et al., 2006

GSRS, Gastrointestinal Symptom Rating Scale; <sup>13</sup>C-UBT; <sup>13</sup>C Urea Breath Test.

## REFERENCES

- Dore, M. P., Cuccu, M., Pes, G. M., Manca, A., and Graham, D. Y. (2014). *Lactobacillus reuteri* in the treatment of *Helicobacter pylori* infection. *Intern. Emerg. Med.* 9, 649–654. doi: 10.1007/s11739-013-013-z
- Efrati, C., Nicolini, G., Cannaviello, C., O'sed, N. P., and Valabrega, S. (2012). *Helicobacter pylori* eradication: sequential therapy and *Lactobacillus reuteri* supplementation. *World J. Gastroenterol.* 18, 6250–6254. doi: 10.3748/wjg.v18.i43.6250
- Emara, M. H., Mohamed, S. Y., and Abdel-Aziz, H. R. (2014). *Lactobacillus reuteri* in management of *Helicobacter pylori* infection in dyspeptic patients: a double-blind placebo-controlled randomized clinical trial. *Therap. Adv. Gastroenterol.* 7, 4–13. doi: 10.1177/1756283X13503514
- Francavilla, R., Lionetti, E., Castellaneta, S. P., Magistà, A. M., Maurogiovanni, G., Bucci, N., et al. (2008). Inhibition of *Helicobacter pylori* infection in humans by *Lactobacillus reuteri* ATCC 55730 and effect on eradication therapy: a pilot study. *Helicobacter* 13, 127–134. doi: 10.1111/j.1523-5378.2008.00593.x
- Francavilla, R., Polimeno, L., Demichina, A., Maurogiovanni, G., Principi, B., Scaccianoce, G., et al. (2014). *Lactobacillus reuteri* strain combination in *Helicobacter pylori* infection: a randomized, double-blind, placebo-controlled study. *J. Clin. Gastroenterol.* 48, 407–413. doi: 10.1097/MCG.0000000000000007
- Imase, K., Tanaka, A., Tokunaga, K., Sugano, H., Ishida, H., and Takahashi, S. (2007). *Lactobacillus reuteri* tablets suppress *Helicobacter pylori* infection—a double-blind randomised placebo-controlled cross-over clinical study. *Kansenshogaku Zasshi* 81, 387–393. doi: 10.11150/kansenshogakuzasshi1970.81.387
- Lionetti, E., Miniello, V. L., Castellaneta, S. P., Magistà, A. M., de Canio, A., Maurogiovanni, G., et al. (2006). *Lactobacillus reuteri* therapy to reduce side-effects during anti-*Helicobacter pylori* treatment in children: a randomized placebo controlled trial. *Aliment. Pharmacol. Ther.* 24, 1461–1468. doi: 10.1111/j.1365-2036.2006.03145.x
- Ojetti, V., Bruno, G., Ainora, M. E., Gigante, G., Rizzo, G., Roccarina, D., et al. (2012). Impact of *Lactobacillus reuteri* supplementation on anti-*Helicobacter pylori* levofloxacin-based second-line therapy. *Gastroenterol. Res. Pract.* 2012:740381. doi: 10.1155/2012/740381
- Scaccianoce, G., Zullo, A., Hassan, C., Gentili, F., Cristofari, F., Cardinale, V., et al. (2008). Triple therapies plus different probiotics for

- Helicobacter pylori* eradication. *Eur. Rev. Med. Pharmacol. Sci.* 12, 251–256.
- Tolone, S., Pellino, V., Vitaliti, G., Lanzafame, A., and Tolone, C. (2012). Evaluation of *Helicobacter Pylori* eradication in pediatric patients by triple therapy plus lactoferrin and probiotics compared to triple therapy alone. *Ital. J. Pediatr.* 38:63. doi: 10.1186/1824-7288-38-63

Copyright © 2019 Tyagi and Prasad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.